Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
2
50%
Ph early_phase_1
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

unknown125%
completed250%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

NCT05879432
completedphase_2

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
completedearly_phase_1

A Phase I Study to Evaluate LSALT Peptide

NCT03772678
unknownphase_3

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

NCT04330690

Clinical Trials (4)

Showing 4 of 4 trials
NCT05879432Phase 2

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Recruiting
NCT04402957Phase 2

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Completed
NCT03772678Early Phase 1

A Phase I Study to Evaluate LSALT Peptide

Completed
NCT04330690Phase 3

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4